University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
March 15, 2024 07:05 ET
|
Arch Biopartners
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of...
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
March 07, 2024 07:26 ET
|
Arch Biopartners
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in...
Dr. Lisandro Montalvo-Burke Joins Healthmap Solutions as Medical Director for Puerto Rico
February 13, 2024 08:00 ET
|
Healthmap Solutions
Healthmap Solutions, Inc. has named Lisandro Montalvo-Burke, MD as its new Medical Director in Puerto Rico.
France Kidney Function Tests Market Forecasts & Opportunities 2018-2028: Dipsticks and Hospitals & Clinics Secure Leading Positions
January 30, 2024 07:51 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "France Kidney Function Tests Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ...
Kidney Renal Function Test Market Size Worth USD 1,599.0 Million in 2032 | Emergen Research
January 29, 2024 09:55 ET
|
Emergen Research
Vancouver, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The global kidney/renal function test market size was USD 845.9 Million in 2022 and is expected to register a revenue CAGR of 6.5% during the forecast...
Global Chronic Kidney Disease Market Poised for Growth, Projected to Reach $83.6 Billion by 2030
January 23, 2024 03:08 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
December 21, 2023 07:30 ET
|
Arch Biopartners
TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
December 07, 2023 07:00 ET
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
September 22, 2023 07:00 ET
|
Arch Biopartners
TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of...